Natera.
company in San Carlos, United States
- Reports this week
- 1
- Active events
- 0
- Connections
- 97
What's happening
Earlier this month
-
Natera plans commercial launch in Japan by end of 2026 after the PMDA approved its Signatera test for colorectal cancer.Some support5 reports
-
Steven Chapman was appointed as the CEO of Natera on August 14, 2025.Some support4 reports
-
Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Well supported6 reports2 developments inside
-
Natera's Signatera test is being used in the AFT-70 NAVIGATE trial, which is co-funded and collaborated on by Genentech.Some support1 report
-
Natera and Fractyl Health, biotech companies, traded on the NASDAQ stock exchange on September 1, 2026.Some support1 report
One to three months ago
-
George Soros and Stanley Druckenmiller traded together, and Druckenmiller's family office holds Natera.Some support1 report
-
Natera filed disclosures with the SEC and its stock traded on the Nasdaq exchange on September 3, 2026. The firm also received research commentary from TD Cowen.Some support1 report
-
Morgan Stanley reaffirmed a positive outlook on the stock of Natera on August 26, 2026.Some support1 report
-
Duquesne Family Office added Insmed as a smaller biotech buy and purchased shares in Natera as a top holding.Some support1 report
-
Investor Stanley Druckenmiller made significant portfolio moves on August 8th, including adding stakes in STMicroelectronics, Intel, and Micron, while also managing positions in Natera, Broadcom, Google, and Amazon.Well supported6 reports
-
A co-founder of Natera graduated from Stanford University and previously worked in Harvard's genetics department.Some support1 report
-
Natera develops and commercializes the Panorama test, highlighting competition among medical companies.Some support2 reports
-
Stanley Druckenmiller increased his largest stock position in Natera, a company listed on U.S. markets.Well supported4 reports
-
Natera trades on the Nasdaq stock exchange.Well supported8 reports
Gone quiet
No new reports in 90+ days-
Tempus and Natera are operating in the competitive field of ctDNA diagnostics.Some support1 report1 development inside
-
Tempus and Natera are subject to new financial analysis from BNP Paribas and William Blair regarding valuation and strategic fit.Some support1 report
-
Natera and Eledon Pharmaceuticals have formed a partnership to utilize Natera's Prospera test.Some support1 report
-
Goldman Sachs initiated coverage on Natera, which subsequently announced a collaboration with CytoDyn.Some support1 report
-
Natera is finalizing its premarket approval application for an assay that predicts benefit from a drug developed by Roche, discussed in the context of the IMvigor011 trial.Some support2 reports
-
Bio company DQS is involved in the Prospera Heart test, while Natera presented data at WTC in San Francisco.Some support1 report
-
Leerink partners reiterated an Outperform rating on Natera on June 24, 2025.Speculative1 report
-
LoveSac and Natera were mentioned as successful companies and market-beating stocks on June 26, 2025.Speculative1 report
-
Natera presented research data at ESMO GI in Barcelona on July 2, 2025.Speculative1 report
-
Natera announced data from a study led by Yoshiaki Nakamura in Austin.Speculative1 report
-
Natera, a global diagnostics company, is involved in a business context with Bruker, which develops solutions for the US and distributes scientific instruments across Europe.Some support2 reports
-
Natera is recognized as a global leader in cell-free DNA testing, and Suphamai Bunnapradist is the principal investigator of the PEDAL study.Some support1 report
-
Natera has initiated the Phase II TEODOR trial.Some support1 report
-
Natera is based in Austin, Texas.Some support3 reports1 development inside
-
Natera offers molecular testing services globally and operates a cinema advertising network in North America.Some support1 report
-
Natera received an Outperform rating from Evercore ISI on July 31, 2025.Some support1 report
-
Incyte and Natera are identified as peers within the biotechnology segment.Some support3 reports
-
Natera announced the launch of Fetal Focus in Austin.Some support1 report
-
Natera utilizes Horizon technology for carrier screening purposes.Some support1 report
-
Zacks Investment Research published stock analysis reports concerning Natera on August 8, 2025.Some support1 report
-
Natera and Royal Gold were highlighted as potential undervalued investments on August 11, 2025.Some support1 report
-
Natera develops genetic tests for various applications and designs custom solutions for medical devices in collaboration with UFP Technologies.Some support1 report
-
Natera presented research data at IASLC World Conference and WCLC.Some support1 report
-
Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.Well supported3 reports2 developments inside
-
NeoGenomics wins a patent lawsuit and submits a product for clinical reimbursement coverage.Some support1 report
-
Guardant Health and Natera face a lawsuit regarding disputes over cancer diagnostics and misleading advertising claims, presided over by Judge Edward Chen.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Natera
Events traced to Natera, step by step, newest firstAround Natera this week
News at the entities that move Natera most-
FDA StructuralHelus Pharma is seeking review from the FDA for its drug candidate HLP003, led by company executive Eric So.Moves Natera
-
Vermont TransactionalThe Liberty Union Party is active in Vermont's political landscape, and Phil Scott is running as a Republican candidate.Moves Natera
-
Medicare StructuralPretax 401(k) savings are being converted into Roth accounts.Moves Natera
-
Nasdaq StructuralXrp Etf began operations on June 1, 2026, utilizing a subsidiary located in the Cayman Islands.Moves Natera
-
Goldman Sachs OperationalSolaria's data centre deal in Uruguay drew investor attention, with Gandolfi assessing associated risks.Moves Natera
-
Guardant Health OperationalBrightSpring Health Services and Guardant Health have both been listed on the Nasdaq stock exchange.Moves Natera
Connections
The 35 strongest of 97, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Panorama Structural
Natera utilizes, develops, and commercializes Panorama as its core prenatal screening technology.
-
Steven Chapman Structural
Steven Chapman serves as the CEO of Natera.
-
Steve Chapman Structural
Steve Chapman serves as the Chief Executive Officer of Natera.
-
FDA Structural
Natera relies on the FDA for market access, which evaluates and grants approval for its products as a companion diagnostic.
-
NeoGenomics Operational
NeoGenomics and Natera are engaged in active patent litigation and intellectual property disputes.
-
Pharmaceuticals and Medical Devices Agency Structural
The PMDA grants regulatory approvals for Natera's diagnostic tests, establishing a formal dependency.
-
Alliance Foundation Trials Structural
Natera provides MRD monitoring services used in Alliance Foundation Trials' clinical studies.
-
Nasdaq Structural
Natera is a publicly traded company whose listing and trading occurs on the Nasdaq stock exchange.
Show all 35 connections
-
Stanley Druckenmiller Transactional
Stanley Druckenmiller holds a large, leading investment position in Natera, actively accumulating stock.
-
Vermont Transactional
Trust Co. of Vermont purchased shares in Natera.
-
Medicare Structural
Medicare coverage decisions and expansions directly drive the scope and revenue streams of Natera's services.
-
SEC Structural
Natera is subject to mandatory disclosure and regulatory oversight by the SEC.
-
Guardant Health Operational
The two companies are engaged in active competition regarding cancer diagnostics, specifically concerning product claims and market disputes.
-
Regeneron Pharmaceuticals Operational
Both Natera and Regeneron Pharmaceuticals are identified as major competitors in the immuno-oncology market.
-
NRG Oncology Structural
Natera provides diagnostic tests that are incorporated into and utilized by clinical trials sponsored by NRG Oncology.
-
Tempus Operational
Tempus and Natera are direct competitors vying for market share in the ctDNA diagnostics space.
-
Invesco Structural
A fund managed by Invesco holds Natera as a large financial position.
-
Organon & Co. Operational
Both medical companies are noted to be competing for investment capital.
-
Goldman Sachs Operational
Goldman Sachs has begun market coverage and monitoring of Natera, indicating a professional market interaction.
-
TD Cowen Mentioned together
TD Cowen publishes research commentary regarding Natera.
-
Incyte Operational
Incyte and Natera are peers and competitors operating within the immuno-oncology and biotechnology segments.
-
Jim Cramer Mentioned together
Jim Cramer provides commentary on Natera's stock valuation.
-
Morgan Stanley Mentioned together
Morgan Stanley provided market coverage by reaffirming a positive outlook on Natera stock.
-
Agilent Technologies Mentioned together
Both companies operate within the life sciences and diagnostics sector.
-
Stanford University Mentioned together
A co-founder of Natera graduated from Stanford University.
-
Japanese Shared context
Natera received regulatory approval from the Japanese PMDA, allowing it to operate within Japan's jurisdiction.
-
Ark Invest Transactional
Ark Invest trimmed its investment positions in Natera.
-
Nvidia Mentioned together
The companies are frequently co-mentioned in financial media as examples of high-quality, high-performing growth stocks.
-
MarketBeat Mentioned together
MarketBeat lists Natera as a stock to watch, placing it within a thematic group of tracked investments.
-
Mirum Pharmaceuticals Operational
Mirum Pharmaceuticals and Natera are actively competing within the biopharmaceutical sector.
-
Amazon Mentioned together
Natera is mentioned as a top holding within a specific investment portfolio.
-
Harvard Mentioned together
A co-founder of Natera utilized facilities and expertise from the genetics department at Harvard.
-
Austin Shared context
Natera is headquartered and operates laboratories within Austin, Texas.
-
San Carlos Shared context
Natera operates laboratories within the jurisdiction of San Carlos.
-
BNP Paribas Mentioned together
The provided evidence timeline contains only a snapshot regarding BNP Paribas' self-valuation and does not describe any interaction between the two entities.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
3 events- Natera and Fractyl Health, biotech companies, traded on the NASDAQ stock exchange on September 1, 2026.
- George Soros and Stanley Druckenmiller traded together, and Druckenmiller's family office holds Natera.
- Natera filed disclosures with the SEC and its stock traded on the Nasdaq exchange on September 3, 2026. The firm also received research commentary from TD Cowen.
August 2026
5 events- Morgan Stanley reaffirmed a positive outlook on the stock of Natera on August 26, 2026.
- Duquesne Family Office added Insmed as a smaller biotech buy and purchased shares in Natera as a top holding.
- Investor Stanley Druckenmiller made significant portfolio moves on August 8th, including adding stakes in STMicroelectronics, Intel, and Micron, while also managing positions in Natera, Broadcom, Google, and Amazon.
- A co-founder of Natera graduated from Stanford University and previously worked in Harvard's genetics department.
- Stanley Druckenmiller increased his largest stock position in Natera, a company listed on U.S. markets.
Show 2 earlier months
July 2026
2 eventsJune 2026
29 events- Natera plans commercial launch in Japan by end of 2026 after the PMDA approved its Signatera test for colorectal cancer.
- Steven Chapman was appointed as the CEO of Natera on August 14, 2025.
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
- Natera develops and commercializes the Panorama test, highlighting competition among medical companies.
- Tempus and Natera are operating in the competitive field of ctDNA diagnostics.
- Natera and Eledon Pharmaceuticals have formed a partnership to utilize Natera's Prospera test.
- Goldman Sachs initiated coverage on Natera, which subsequently announced a collaboration with CytoDyn.
- Natera is finalizing its premarket approval application for an assay that predicts benefit from a drug developed by Roche, discussed in the context of the IMvigor011 trial.
- Bio company DQS is involved in the Prospera Heart test, while Natera presented data at WTC in San Francisco.
- Leerink partners reiterated an Outperform rating on Natera on June 24, 2025.
- LoveSac and Natera were mentioned as successful companies and market-beating stocks on June 26, 2025.
- Natera presented research data at ESMO GI in Barcelona on July 2, 2025.
- Natera announced data from a study led by Yoshiaki Nakamura in Austin.
- Natera, a global diagnostics company, is involved in a business context with Bruker, which develops solutions for the US and distributes scientific instruments across Europe.
- Natera is recognized as a global leader in cell-free DNA testing, and Suphamai Bunnapradist is the principal investigator of the PEDAL study.
- Natera has initiated the Phase II TEODOR trial.
- Natera is based in Austin, Texas.
- Natera offers molecular testing services globally and operates a cinema advertising network in North America.
- Natera received an Outperform rating from Evercore ISI on July 31, 2025.
- Incyte and Natera are identified as peers within the biotechnology segment.
- Natera announced the launch of Fetal Focus in Austin.
- Natera utilizes Horizon technology for carrier screening purposes.
- Zacks Investment Research published stock analysis reports concerning Natera on August 8, 2025.
- Natera and Royal Gold were highlighted as potential undervalued investments on August 11, 2025.
- Natera develops genetic tests for various applications and designs custom solutions for medical devices in collaboration with UFP Technologies.
- Natera presented research data at IASLC World Conference and WCLC.
- Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.
- NeoGenomics wins a patent lawsuit and submits a product for clinical reimbursement coverage.
- Guardant Health and Natera face a lawsuit regarding disputes over cancer diagnostics and misleading advertising claims, presided over by Judge Edward Chen.